On October 30, 2019 Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, reported that Francesco M. Marincola, M.D., chief scientific officer of Refuge, will present during the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting & Pre-Conference Programs (SITC 2019) (Press release, Refuge Biotechnologies, OCT 30, 2019, View Source [SID1234550059]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Marincola will deliver a scientific overview detailing Refuge’s platform technology during the Novel Multi-Targeted Therapeutic Platform program, held November 6 at the Gaylord National Hotel & Convention Center in Maryland. The overview will include recent data from Refuge’s proprietary receptor-dCas platform and its multi-functional therapeutic applications.
"The work being done at Refuge Biotechnologies builds upon the promise of CRISPR interference and CRISPR activation, and has demonstrated the ability to develop a novel therapy that induces gene modulation of multiple genes simultaneously without making permanent edits to the genome," said Dr. Marincola. "This capability has the potential to be combined with numerous therapeutic mechanisms in a single customizable treatment. We look forward to sharing progress as we advance towards the clinic."
Details of the presentation are as follows:
Title: Contextual reprogramming of T cells for multi-targeted therapeutics: checkpoint blockade, immune resilience, and stemness to overcome immune resistance and reduce toxicity, all in one cell product
Presenter: Francesco M. Marincola, M.D.
Date and Time: Wednesday, November 6, 2019 at 4:15 p.m. ET
Session 2: Novel Platforms and Innovation